Key Takeaways The race to develop the most effective metabolic research peptide has intensified. Two compounds have pulled ahead of the pack: Retatrutide (Eli Lilly’s triple agonist) and Tirzepatide (Eli Lilly’s dual agonist, already marketed as Mounjaro/Zepbound). For Australian researchers designing metabolic protocols, understanding the precise differences between these two powerhouses isn’t optional — it’s […]
Tag Archives: triple agonist peptide
Key Takeaways Retatrutide — also known by its developmental code LY3437943 — has rapidly emerged as the most promising compound in modern metabolic research. In Phase 2 trials, it achieved something no other pharmacological agent has: a 24.2% mean weight loss in participants. That’s not a typo. For Australian researchers, biohackers and peptide scientists, understanding […]
Retatrutide (Reta) is a research peptide that works on three key systems in the body to help control hunger, blood sugar, and fat use. Early studies show strong weight loss and better blood sugar control with once-weekly use. This guide explains how to mix, dose, and use it properly for research.





